Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$13.25 USD
-0.16 (-1.19%)
Updated Apr 22, 2024 10:44 AM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 130 | 92 | 147 | 216 | 274 |
Receivables | 0 | 1 | 0 | 1 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 7 | 7 | 5 |
Total Current Assets | 134 | 97 | 154 | 224 | 283 |
Net Property & Equipment | 0 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 28 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 42 | 42 |
Deposits & Other Assets | 0 | 1 | 2 | 6 | 2 |
Total Assets | 137 | 102 | 191 | 283 | 340 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 3 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 10 | 10 | 16 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 31 | 0 | 0 | 0 | 6 |
Total Current Liabilities | 39 | 16 | 16 | 24 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 55 | 3 | 3 | 12 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 19 | 22 | 43 | 67 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 827 | 808 | 801 | 742 | 713 |
Retained Earnings | -786 | -725 | -631 | -502 | -439 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 41 | 83 | 169 | 241 | 273 |
Total Liabilities & Shareholder's Equity | 137 | 102 | 191 | 283 | 340 |
Total Common Equity | 41 | 83 | 169 | 241 | 273 |
Shares Outstanding | 5.40 | 4.00 | 3.90 | 2.70 | 2.10 |
Book Value Per Share | 7.61 | 20.67 | 43.32 | 89.10 | 130.10 |
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 130 | 46 | 60 | 73 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 3 | 4 | 6 |
Total Current Assets | NA | 134 | 50 | 64 | 80 |
Net Property & Equipment | NA | 0 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 1 | 0 | 0 |
Total Assets | NA | 137 | 52 | 67 | 83 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7 | 6 | 6 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 31 | 0 | 0 | 0 |
Total Current Liabilities | NA | 39 | 7 | 9 | 10 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 55 | 3 | 3 | 3 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 96 | 10 | 12 | 13 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 827 | 817 | 816 | 814 |
Retained Earnings | NA | -786 | -775 | -760 | -743 |
Other Equity | NA | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 41 | 42 | 55 | 70 |
Total Liabilities & Shareholder's Equity | NA | 137 | 52 | 67 | 83 |
Total Common Equity | 0 | 41 | 42 | 55 | 70 |
Shares Outstanding | 5.40 | 5.40 | 4.30 | 4.30 | 4.30 |
Book Value Per Share | 0.00 | 7.61 | 9.70 | 12.78 | 16.36 |